SEC Company Response from CYTOKINETICS INC (CYTK) (CIK 0001061983) (CYTK) — Apr 4, 2011
CYTOKINETICS INC (CYTK) (CIK 0001061983)
Date: April 4, 2011 · CIK: 0001061983 · Accession: 0000950123-11-032582
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50633
Referenced dates: March 25, 2011
Letter
Michael E. Tenta
VIA EDGAR
(650) 843-5636
mtenta@cooley.com
April 4, 2011
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn:
Jeffrey Riedler
Scot Foley
RE:
Cytokinetics, Incorporated
Preliminary Proxy Statement on Schedule 14A
Filed March 17, 2011
File No. 000-50633
Ladies and Gentlemen:
On behalf of Cytokinetics, Incorporated (the “Company”), we are submitting this letter in response to the comment of the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated March 25, 2011 (the “Comment Letter”). Set forth below is the comment in your Comment Letter followed by our response.
Proposal Three, page 5
1.
Your proposal to amend your Certificate of Incorporation to increase the number of authorized shares of common stock does not state whether you have any current plans, agreements, understandings, etc. with respect to the additional shares you propose to have authorized. If you have any such plans, agreements, understandings, etc., please note this in your disclosure and describe them. If you have none, please include a statement to that effect.
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company did not receive the Comment Letter until March 31, 2011, when it was delivered by the U.S. Postal Service. In reliance on Rule 14a-6, the Company filed with the Commission and began printing in hardcopy its Definitive Proxy Statement on Schedule 14A on March 28, 2011, having not received comment from the Commission within ten days of filing its Preliminary Proxy Statement on Schedule 14A on March 17, 2011. The Company respectfully advises the Staff that it is therefore no longer practicable to amend the disclosure in its Definitive Proxy Statement on Schedule 14A.
Further to discussions between the undersigned and Mr. Foley, we understand that the Commission also transmitted the Comment Letter by facsimile. Regrettably, the Company did not receive the facsimile. As discussed with Mr. Foley, we understand that in light of the
FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM
Securities and Exchange Commission
April 4, 2011
Page Two
circumstances, the Staff will not require an amendment or supplement to the Company’s Definitive Proxy Statement. The Company supplementally advises the Staff that the Company does not have any current plans, agreements, understandings, etc. with respect to the additional shares of common stock that the Company proposes to have authorized.
*****
Please do not hesitate to contact me at (650) 843-5636 if you have any questions or would like any additional information regarding this response.
Sincerely,
/s/ Michael E. Tenta
Show Raw Text
CORRESP
1
filename1.htm
corresp
Michael E. Tenta
VIA EDGAR
(650) 843-5636
mtenta@cooley.com
April 4, 2011
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn:
Jeffrey Riedler
Scot Foley
RE:
Cytokinetics, Incorporated
Preliminary Proxy Statement on Schedule 14A
Filed March 17, 2011
File No. 000-50633
Ladies and Gentlemen:
On behalf of Cytokinetics, Incorporated (the “Company”), we are submitting this letter in response
to the comment of the Staff (the “Staff”) of the Securities and Exchange Commission (the
“Commission”) by letter dated March 25, 2011 (the “Comment Letter”). Set forth below is the comment
in your Comment Letter followed by our response.
Proposal Three, page 5
1.
Your proposal to amend your Certificate of Incorporation to increase the number
of authorized shares of common stock does not state whether you have any current plans,
agreements, understandings, etc. with respect to the additional shares you propose to
have authorized. If you have any such plans, agreements, understandings, etc., please
note this in your disclosure and describe them. If you have none, please include a
statement to that effect.
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company
did not receive the Comment Letter until March 31, 2011, when it was delivered by the U.S. Postal
Service. In reliance on Rule 14a-6, the Company filed with the Commission and began printing in
hardcopy its Definitive Proxy Statement on Schedule 14A on March 28, 2011, having not received
comment from the Commission within ten days of filing its Preliminary Proxy Statement on Schedule
14A on March 17, 2011. The Company respectfully advises the Staff that it is therefore no longer
practicable to amend the disclosure in its Definitive Proxy Statement on Schedule 14A.
Further to discussions between the undersigned and Mr. Foley, we understand that the Commission
also transmitted the Comment Letter by facsimile. Regrettably, the Company did not receive the
facsimile. As discussed with Mr. Foley, we understand that in light of the
FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM
Securities and Exchange Commission
April 4, 2011
Page Two
circumstances, the Staff
will not require an amendment or supplement to the Company’s Definitive Proxy Statement. The
Company supplementally advises the Staff that the Company does not have any current plans,
agreements, understandings, etc. with respect to the additional shares of common stock that the
Company proposes to have authorized.
*****
Please do not hesitate to contact me at (650) 843-5636 if you have any questions or would like any
additional information regarding this response.
Sincerely,
/s/ Michael E. Tenta
Michael E. Tenta
cc:
Sharon A. Barbari, Cytokinetics, Incorporated
Robert L. Jones, Cooley LLP
930184 v2/HN
FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM